CERo Therapeutics Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead drug candidate, CER-1236, aimed at treating acute myeloid ...
Squamous non-small cell lung cancer (sqNSCLC) is an aggressive subtype of lung cancer accounting for approximately 25-30% of all NSCLC cases, the most common type of lung cancer1. The 5-year relative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback